14 @ HalalXtra September-October . 2023
Duopharma HAPI facilitates access to halal medicines as part of its sustainability efforts
14 @ HalalXtra September-October . 2023
TECHNOLOGY
Pioneering halal medical solutions
Duopharma HAPI facilitates access to halal medicines as part of its sustainability efforts
IN THE heart of Glenmarie , Selangor , an innovative stride towards halal medical solutions is gaining momentum . Duopharma HAPI ( Highly Potent Active Pharmaceutical Ingredient ) a subsidiary of Duopharma Biotech Berhad , is emerging as a symbol of pioneering spirit and unwavering dedication .
Established in July 2019 , this state-of-the-art facility signifies Malaysia ’ s inaugural cancer medicine manufacturing plant . It reflects the company ’ s resolute commitment to advancing healthcare solutions locally and globally .
Duopharma HAPI stands at the forefront of innovation as the healthcare landscape evolves , reshaping how cancer medications are manufactured and delivered .
The facility ’ s strategic location in Glenmarie , Selangor , positions it as a centre of excellence , combining cutting-edge technology with halal integrity to meet the diverse needs of patients worldwide .
With its establishment , Duopharma Biotech showcases its dedication to addressing the critical paucity of accessible and affordable cancer treatments within Malaysia and across borders .
FACILITIES ALIGNED WITH GLOBAL STANDARDS
Duopharma HAPI ’ s manufacturing facility embodies precision , innovation , and halal values .
Tailored to craft an extensive range of oncology and cytotoxic drugs , the facility adheres to the most stringent global standards of production , quality control , and safety .
The achievement of the prestigious Good Manufacturing Practice ( GMP ) certification from the Malaysian National Pharmaceutical Regulatory Agency ( NPRA ) underscores its commitment to uncompromising quality and patient well-being .
This certification is a testament to the facility ’ s unwavering adherence to international benchmarks , a crucial element in ensuring the efficacy and safety of the medications produced .
EMPOWERING THE MEDICAL ARSENAL
With an annual production capacity of 8.8 million units of tablets , Duopharma HAPI is not merely a facility ; it ’ s a beacon of hope for patients and healthcare professionals alike .
The facility specialises in creating a diverse portfolio of clinically validated oncology drugs and addresses various cancer types .
From breast cancer to lung cancer , colorectal cancer , cervical cancer , and blood cancer , these groundbreaking medications offer hope to those battling these formidable diseases .
Beyond oncology , the facility ’ s capabilities extend to producing medications that address hormonal imbalances , cardiovascular issues , central nervous system disorders , and musculoskeletal conditions , making it a versatile asset in the quest for holistic healthcare solutions .
MILESTONES OF EXCELLENCE
The journey of Duopharma HAPI is marked by achievements that redefine the boundaries of medical innovation and patient care :
Group Managing Director of Duopharma Biotech Leonard Ariff Abdul Shatar remarked : “ In 2019 , the facility proudly produced Letrozole , a pioneering cancer molecule . This achievement led to its commercialisation under the brand Letronat in June 2020 .
“ Subsequently , the brand was rebranded to Lebreta in July 2021 , signifying a significant stride in treating postmenopausal women with breast cancer .”
COMMITTED TO HALAL EXCELLENCE
Last year bore witness to a pivotal achievement as Duopharma HAPI obtained a halal certification for LEB- RETA from the Department of Islamic Development Malaysia ( JAKIM )
This certification not only underlines the company ’ s unwavering dedication to halal medical solutions but also reinforces its commitment to catering to patients ’ diverse cultural and ethical preferences .
“ This milestone Halal certification for an oncology product manufactured at Duopharma Biotech ’ s HAPI facility is in line with our ESG commitment , where one of our Key Focus Areas is Access to Medicine ,” said Leonard Ariff .
“ We aspire to produce a holistic range of safe , effective , quality Halal-certified products to enhance inclusivity in healthcare , enabling all patients to have choices in the therapies and medications they need for their well-being .”
In 2023 , the facility added another feather to its cap by successfully launching the commercial production of the Trevive tablet . This locally manufactured cancer drug further solidifies Duopharma HAPI ’ s position as a critical player in advancing medical solutions
Duopharma HAPI facility , Glenmarie , Shah Alam .
within Malaysia and beyond . VISION FOR THE FUTURE
Continuing its trailblazing journey , Duopharma HAPI achieved a significant breakthrough by completing the pilot batch for a specific lung cancer treatment in July 2023 .
The company now diligently works towards obtaining NPRA approval , with a targeted achievement set for June 2024 . This remarkable feat not only underscores the facility ’ s capabilities but also reaffirms its commitment to continuous innovation and pursuit of medical excellence .
Facilities and the operations in Duopharma HAPI , Glenmarie , Shah Alam .
Duopharma HAPI ’ s journey is a testament to the transformative power of halal medical solutions .
“ By synergising cutting-edge technology , a diverse product portfolio , and a steadfast commitment to excellence , the facility is redefining the paradigm of cancer drug manufacturing on both a national and global scale ,” added Leonard Ariff .
As Duopharma HAPI continues to surmount remarkable milestones , it remains poised to drive a new era of healthcare solutions anchored in halal values and unwavering dedication to patient well-being .–
Xtra